Tesamorelin Research Peptide

Tesamorelin is a modified analogue of human growth hormone-releasing hormone.

• Tesamorelin, Tesa, and Tesa peptide refer to the same active compound, while product names identify specific regulated formulations.
• It is mechanistically different from ghrelin-receptor secretagogues such as Ipamorelin.

Tesamorelin binds to GHRH receptors on pituitary somatotroph cells.

• Receptor activation stimulates synthesis and pulsatile release of endogenous growth hormone, followed by changes in IGF-1 and related binding proteins.
• Its pathway differs from administering growth hormone directly and from the albumin-binding DAC design of CJC-1295.
• This category covers receptor biology, endocrine markers, formulation, storage, testing, and comparisons with related compounds.

Tesamorelin has controlled human evidence and an FDA-approved product for a defined indication and population.

• That evidence does not automatically apply to other indications, compounded preparations, or research-labeled material.
• Formulation identity, excipients, concentration, sterility, and regulatory status remain product-specific questions.